Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells

Anti-Cancer Drugs

Volumn 18, Issue 6, 2007, Pages 677-686

  Fujita, Takeo ^a   Doihara, Hiroyoshi ^a   Washio, Kazuhiro ^b   Ino, Hideo ^a   Murakami, Masakazu ^a   Naito, Minoru ^a   Shimizu, Nobuyoshi ^a  

^a OKAYAMA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Japan Labour Health and Welfare Organization   (Japan)

Author keywords

Akt; Bortezomib (PS341, Velcade); ERK; Gastric cancer; Nuclear factor B

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BORTEZOMIB; DOXORUBICIN; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PACLITAXEL; PROTEASOME INHIBITOR; PROTEIN KINASE B; PROTEIN P21;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG INTERACTION; EXPERIMENTAL MODEL; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; STOMACH NEOPLASMS;

EID: 34548357028     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32808bf9d8     Document Type: Article

References (47)

1. Richardson PG. Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol 2003; 1:596-600.
2. Vandenbroucke JP, Kroep JR. Bortezomib in multiple myeloma. N Engl J Med 2005; 353:1297-1298.
3. Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005; 104:2141-2148.
4. Adams J, Kauffman M. Development of the proteasome inhibitor velcade (bortezomib). Cancer Invest 2004; 22:304-311.
5. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005; 23:4776-4789.
6. Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 2005; 11:5526-5533.
7. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T, et al. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 2001; 61:1029-1037.
8. Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, et al. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 2005; 117:376-380.
9. Baoping Y, Guoyong H, Jieping Y, Zongxue R, Hesheng L. Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line. Dig Dis Sci 2004; 49:948-953.
10. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
11. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18:2241-2251.
12. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11:1475-1489.
13. Orlowski RZ, Dees EC. The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res 2003; 5:1-7.
14. Banerjee D, Lifeshitz A. Potential of the proteasome inhibitor MG-132 as an anticancer agent, alone and in combination. Anticancer Res 2001; 21:3941-3948.
15. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 2002; 6:493-500.
16. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T,Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-dependent prostate cancer. J Clin Oncol 2004; 22:2108-2121.
17. Lenz HJ. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 2003; 29:41-48.
18. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 6:2377-2380.
19. Hazlehurst LA, Valkov N,Wisner L, Storey JA, Boulware D, Sullivan DM, et al. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 2001; 98:1897-1903.
20. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002; 22:14374-14379.
21. Tanaka R, Ariyama H, Qin B, Shibata Y, Takii Y, Kusaba H, et al. Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. Oncol Rep 2005; 3:683-688.
22. Emoto T, Yoshikawa K, Fujii M, Nezu R, Dousei T, Fujikawa M, et al. Clinical study of weekly administration of paclitaxel for advanced and metastatic gastric cancer. Gan To Kagaku Ryoho 2003; 6:809-815. [Japanese].
23. Liang B, Wang S, Zhu XG, Yu YX, Cui ZR, Yu YZ. Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer. World J Gastroenterol 2005; 11:623-628.
24. Kang W, Nielsen O, Fenger C, Leslie G, Holmskov U, Reid KB. Induction of DMBT1 expression by reduced ERK activity during a gastric mucosa differentiation-like process and its association with human gastric cancer. Carcinogenesis 2005; 26:1129-1137.
25. Lee BL, Lee HS, Jung J, Cho SJ, Chung HY, Kim WH, et al. Nuclear factor-κβ activation correlates with better prognosis and Akt activation in human gastric cancer. Clin Cancer Res 2004; 11:2518-2525.
26. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23:5281-5293.
27. Rinehart J, Adjei AA, Lorusso PM,Waterhouse D, Hecht JR, Natale RB, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22:4456-4462.
28. Juttner S, Cramer T, Wessler S, Walduck A, Gao F, Schmitz F, et al. Helicobacter pylori stimulates host cyclooxygenase-2 gene transcription: critical importance of MEK/ERK-dependent activation of USF1/-2 and CREB transcription factors. Cell Microbiol 2003; 5:821-834.
29. Zhu Y, Zhong X, Zheng S, Du Q, Xu W. Transformed immortalized gastric epithelial cells by virulence factor CagA of Helicobacter pylori through Erk mitogen-activated protein kinase pathway. Oncogene 2005; 24:3886-3895.
30. Kim MH, Yoo HS, Chang HJ, Hong MH, Kim HD, Chung IJ, et al. Urokinase plasminogen activator receptor is upregulated by Helicobacter pylori in human gastric cancer AGS cells via ERK, JNK, and AP-1. Biochem Biophys Res Commun 2005; 333:874-880.
31. Mitsuno Y, Yoshida H, Maeda S, Ogura K, Hirata Y, Kawabe T, et al. Helicobacter pylori induced transactivation of SRE and AP-1 through the ERK signalling pathway in gastric cancer cells. Gut 2001; 49:18-22.
32. Osaki M, Kase S, Adachi K, Takeda A, Hashimoto K, Ito H. Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J Cancer Res Clin Oncol 2004; 130:8-14.
33. Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002; 8:1136-1144.
34. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002; 19:16639-16647.
35. Camp ER, Li J, Minnich DJ, Brank A, Moldawer LL, Mackay SL, et al. Inducible nuclear factor-κB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 2004; 199:249-258.
36. Jung M, Dritschilo A. NF-κB signaling pathway as a target for human tumor radiosensitization. Semin Radiat Oncol 2001; 11:346-351.
37. Muerkoster S, Arlt A, Witt M, Gehrz A, Haye S, March C, et al. Usage tpdel of the NF-κB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreas cancer. Int J Cancer 2003; 104:469-476.
38. Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 2003; 21:4239-4247.
39. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, et al. NF-κB transcription factor induced drug resistance through MDR1 expression in cancer cells. Oncogene 2003; 22:90-97.
40. Fujita T, Washio K, Takabatake D, Takahashi H, Yoshitomi S, Tsukuda K, et al. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int J Cancer 2005; 117:670-682.
41. Camp ER, Li J, Minnich DJ, Brank A, Moldawer LL, MacKay SL, et al. Inducible nuclear factor-κB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 2004; 199:249-258.
42. Uetsuka H, Haisa M, Kimura M, Gunduz M, Kaneda Y, Ohkawa T, et al. Inhibition of inducible NF-κB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 2003; 289:27-35.
43. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 18:6853-6866.
44. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 2004; 54:343-353.
45. Cardoso F, Durbecq V, Laes JF, Badran B, Lagneaux L, Bex F, et al. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Mol Cancer Ther 2006; 12:3042-3051.
46. Ocean AJ, Schnoll-Sussman F, Chen X, Holloway S, Wright J, Wadler S. Phase II study of PS-341 (VELCADE, bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). Proc Am Soc Clin Oncol 2005. 2005 Gastrointestinal Cancers Symposium, abstract 31.
47. Shah MA, Holen K, Singh D, Kemeny M, Levner A, Cox L, et al. A multicenter, two-stage, Phase II study of PS-341 in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) Adenocarcinoma. Proc Am Society Clin Oncol 2005. 2005 Gastrointestinal Cancers Symposium, abstract 41.